Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115,
Caroline Robert, Brian Gastman, Helen Gogas, Piotr Rutkowski, Georgina V. Long, Marya Chaney, Harshada Joshi, Yulin Lin, Wendy Snyder, Jason Chesney
Topics & Concepts
PembrolizumabMedicineOpen labelMelanomaOncolytic virusOncologyInternal medicineCancer researchImmunotherapyClinical trialCancerCancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and ManagementMelanoma and MAPK Pathways